Arcturus Therapeutics Holdings, Inc. (ARCT)
12.16
+0.09
(+0.75%)
USD |
NASDAQ |
Oct 29, 16:00
12.15
-0.01
(-0.08%)
After-Hours: 20:00
Arcturus Therapeutics Holdings Enterprise Value : 174.52M for Oct. 28, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 28, 2026 | 174.52M |
| October 27, 2026 | 150.64M |
| October 26, 2026 | 113.12M |
| October 23, 2026 | 111.13M |
| October 22, 2026 | 136.43M |
| October 21, 2026 | 146.09M |
| October 20, 2026 | 143.53M |
| October 19, 2026 | 127.62M |
| October 16, 2026 | 125.34M |
| October 15, 2026 | 151.78M |
| October 14, 2026 | 147.51M |
| October 13, 2026 | 173.38M |
| October 12, 2026 | 189.86M |
| October 09, 2026 | 221.98M |
| October 08, 2026 | 197.25M |
| October 07, 2026 | 194.27M |
| October 06, 2026 | 200.95M |
| October 05, 2026 | 248.13M |
| October 02, 2026 | 201.80M |
| October 01, 2026 | 206.92M |
| September 30, 2026 | 220.56M |
| September 29, 2026 | 220.85M |
| September 28, 2026 | 242.45M |
| September 25, 2026 | 225.11M |
| September 24, 2026 | 232.78M |
| Date | Value |
|---|---|
| September 23, 2026 | 209.48M |
| September 22, 2026 | 240.17M |
| September 21, 2026 | 248.98M |
| September 18, 2026 | 287.07M |
| September 17, 2026 | 312.65M |
| September 16, 2026 | 274.85M |
| September 15, 2026 | 281.67M |
| September 14, 2026 | 266.04M |
| September 11, 2026 | 250.12M |
| September 10, 2026 | 228.80M |
| September 09, 2026 | 250.40M |
| September 08, 2026 | 275.70M |
| September 04, 2026 | 281.10M |
| September 03, 2026 | 273.71M |
| September 02, 2026 | 307.25M |
| September 01, 2026 | 292.61M |
| August 31, 2026 | 250.97M |
| August 28, 2026 | 263.20M |
| August 27, 2026 | 291.05M |
| August 26, 2026 | 281.39M |
| August 25, 2026 | 270.30M |
| August 24, 2026 | 239.04M |
| August 21, 2026 | 213.74M |
| August 20, 2026 | 143.82M |
| August 19, 2026 | 123.64M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.615B |
| Emergent BioSolutions, Inc. | 811.02M |
| Exelixis, Inc. | 15.82B |
| Ionis Pharmaceuticals, Inc. | 7.572B |
| United Therapeutics Corp. | 22.37B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -23.78M |
| Revenue (Quarterly) | 0.88M |
| Total Expenses (Quarterly) | 24.66M |
| EPS Diluted (Quarterly) | -0.8368 |
| Gross Profit Margin (Quarterly) | 31.82% |
| Profit Margin (Quarterly) | -2.70K% |
| Earnings Yield | -27.26% |
| Normalized Earnings Yield | -25.70 |